Advertisement

Topics

BioLineRx Ltd. and Compugen Ltd. Company Profile

07:34 EDT 21st September 2018 | BioPortfolio

BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx’s current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia has commenced a Phase II/III study; BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction has completed a Phase I/II study and has been out-licensed to Ikaria Inc. for a total deal value of $282.5 million, in addition to sales royalties; BL-5010 for non-surgical removal of skin lesions has completed a Phase I/II study; BL-1021 for neuropathic pain is in Phase I development and BL-7040 for treating Inflammatory Bowel Disease (IBD) has completed Phase I. In addition, BioLineRx has nine products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases.


News Articles [66 Associated News Articles listed on BioPortfolio]

BioLineRx Expands Immuno-Oncology Collaboration with Merck in Pancreatic Cancer

Tel Aviv, Israel, July 30, 2018 – BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the expansion of its immuno-on...

BioLineRx starts Phase l/lla trial of AGI-134 for solid tumours

BioLineRx has commenced a Phase l/lla clinical trial to investigate the safety and tolerability of AGI-134 for the treatment of...Read More... The post BioLineRx starts Phase l/lla trial of AGI-134 fo...

MedImmune to Develop Compugen Immuno-Oncology Antibodies

AstraZeneca’s MedImmune subsidiary has agreed to exclusively license and develop bi-specific and multi-specific immuno-oncology antibody products from Compugen’s pipeline, through a collaboration ...

Compugen inks I-O deal worth over $210 million with AZ unit

Compugen has entered into an exclusive license agreement with MedImmune.

BioLineRx: 'Bench to Bedside to Partner' - Bridging the gap between academia and pharma

In this episode of PharmaTelevision News Review, filmed in Amsterdam at BioEurope Spring 2012, Fintan Walton talks to David Malek, Vice Preident of Business Development of BioLineRx.

Compugen earns $7.8m payment from Bayer

The continued development of cancer drug BAY 1905254 is a major boost for Compugen's ability to successfully identify new mechanisms for treatments using its big data systems.

AZ signs up for access to Compugen’s pipeline

AstraZeneca’s MedImmune has inked a deal with Israeli group Compugen giving it access to the firm’s experimental bi- and multi-specific antibody products.

BioLineRx and Merck Expand Their Prostate Cancer Collaboration

BioLineRx, based in Tel Aviv, Israel, and Merck & Co, based in Kenilworth, New Jersey, announced they are expanding their immuno-oncology collaboration.

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [8 Associated Companies listed on BioPortfolio]

BioLineRx Ltd. and Compugen Ltd.

BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over curr...

BioLineRx, Ltd.

BioLineRx's ultimate mission is to improve the health of people throughout the world with compounds that make for better and longer lives. Founded in 2003 by leaders in the Israeli life-sciences secto...

Compugen Ltd.

Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are b...

Compugen

Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen’s discovery efforts are based...

Compugen Ltd. Compugen Ltd.

Compugen is a leading therapeutic product discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology ...

More Information about "BioLineRx Ltd. and Compugen Ltd." on BioPortfolio

We have published hundreds of BioLineRx Ltd. and Compugen Ltd. news stories on BioPortfolio along with dozens of BioLineRx Ltd. and Compugen Ltd. Clinical Trials and PubMed Articles about BioLineRx Ltd. and Compugen Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioLineRx Ltd. and Compugen Ltd. Companies in our database. You can also find out about relevant BioLineRx Ltd. and Compugen Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Corporate Database Quicklinks



Searches Linking to this Company Record